Last reviewed · How we verify

NCT05102370

A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance

Completed Phase 1 Last updated 27 January 2026
What this trial tests

Phase 1 trial testing Enasidenib in Clonal Cytopenia of Undetermined Significance in 4 participants. Completed in 26 January 2026.

Timeline
6 October 2021
Primary endpoint
26 January 2026
26 January 2026

Quick facts

Lead sponsorMemorial Sloan Kettering Cancer Center
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment4
Start date6 October 2021
Primary completion26 January 2026
Estimated completion26 January 2026
Sites12 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

18 and older, any sex, with Clonal Cytopenia of Undetermined Significance or CCUS Clonal Cytopenia of Undetermined Significance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study researchers think that a drug called enasidenib may help people with clonal cytopenia of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which may improve blood cell counts. The purpose of this study is to find out whether enasidenib is a safe and effective treatment for CCUS.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Altered metabolism in cancer: insights into energy pathways and therapeutic targets.
    Tufail M, Jiang CH, Li N. · · 2024 · cited 265× · PMID 39294640 · DOI 10.1186/s12943-024-02119-3
  2. Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic.
    Bewersdorf JP, Abdel-Wahab O. · · 2022 · cited 36× · PMID 35318270 · DOI 10.1101/gad.349368.122
  3. Clonal hematopoiesis and cardiovascular disease: deciphering interconnections.
    Stein A, Metzeler K, Kubasch AS, Rommel KP, et al · · 2022 · cited 25× · PMID 36355225 · DOI 10.1007/s00395-022-00969-w
  4. Clonal hematopoiesis and hematological malignancy.
    Dunn WG, McLoughlin MA, Vassiliou GS. · · 2024 · cited 19× · PMID 39352393 · DOI 10.1172/jci180065
  5. Pathogenesis and inflammaging in myelodysplastic syndrome.
    Villaume MT, Savona MR. · · 2025 · cited 15× · PMID 39445405 · DOI 10.3324/haematol.2023.284944
  6. Molecular Pathways in Clonal Hematopoiesis: From the Acquisition of Somatic Mutations to Transformation into Hematologic Neoplasm.
    Gaulin C, Kelemen K, Arana Yi C. · · 2022 · cited 11× · PMID 36013314 · DOI 10.3390/life12081135
  7. Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia.
    Sirenko M, Lee S, Sun Z, Chaligne R, et al · · 2025 · cited 9× · PMID 40409258 · DOI 10.1016/j.stem.2025.04.012
  8. A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis.
    Haque T, Shastri A, Desai P, Xie Z, et al · · 2025 · cited 9× · PMID 39653653 · DOI 10.1111/bjh.19925

Verify or expand the search:

Other trials of Enasidenib

Trials testing the same drug.

Other recruiting trials for Clonal Cytopenia of Undetermined Significance

Currently open trials in the same condition.

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05102370.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing